Document ID: chunk:federal_register_of_legislation:F2022L00259:clause:1_1:p2
Version: federal_register_of_legislation:F2022L00259
Segment Type: clause
Provision Reference: sch 1 cl 1 (pt 2/4)
Character Range: 17707–21436

of fluticasone propionate;
         (d)          1,000 micrograms of fluticasone furoate;
         (e)          10,000 micrograms of triamcinolone; or
         (f)           a therapeutically equivalent dose of another inhaled glucocorticoid.
                                  equivalent levels using ambulatory blood pressure measurement means:
         (a)          an average 24 hour blood pressure measurement of greater than or equal to 130 mmHg systolic or greater than or equal to 80 mmHg diastolic; or
         (b)          an average daytime (awake) blood pressure measurement of greater than or equal to 135 mmHg systolic or greater than or equal to 85 mmHg diastolic; or
         (c)          an average nighttime (asleep) blood pressure measurement of greater than or equal to 120 mmHg systolic or greater than or equal to 70 mmHg diastolic.
                               glucocorticoid therapy as specified means:
         (a)          applying a high or very high potency topical glucocorticoid to at least 30% of total skin surface area, daily, for at least 6 months; or
         (b)          inhaling at least 4,000 micrograms of budesonide, or equivalent inhaled glucocorticoid, daily, for at least 6 months; or
         (c)          taking:
            (i)            hydrocortisone, orally or by injection:
                 1. to a cumulative dose of at least 1,500 milligrams; and
                 2. at a minimum dose rate averaging 50 milligrams per day; or
            (ii)         equivalent glucocorticoid therapy, orally or by injection; or
         (d)            using a glucocorticoid concurrently with a drug, daily, for at least 4 weeks, where that drug can inhibit the activity of the metabolising enzyme cytochrome P450 3A4 by at least 30% (moderate to strong inhibition); or
         (e)            using a glucocorticoid concurrently with a drug from the Specified List 3 of drugs, daily, for at least 4 weeks; or
         (f)             using a clobetasol containing oral preparation, daily, for at least 4 weeks; or
         (g)            using glucocorticoid containing enemas, daily, for at least 6 months.
        Note: equivalent glucocorticoid therapy, equivalent inhaled glucocorticoid, high or very high potency topical glucocorticoid and Specified List 3 of drugs are also defined in the Schedule 1 – Dictionary.
                               high or very high potency topical glucocorticoid means:
         (a)          betamethasone dipropionate 0.05%;
         (b)          betamethasone valerate 0.1%;
         (c)          clobetasol proprionate 0.05%;
         (d)          diflucortolone valerate 0.1%;
         (e)          fluocinolone acetonide 0.025%;
         (f)           methylprednisolone 0.1%;
         (g)          mometasone 0.1%;
         (h)          triamcinolone acetonide 0.5%; or
         (i)            another topical glucocorticoid of equivalent potency.
                               hyperparathyroidism means an excess level of parathyroid hormone.
                                  hypertension—see subsection 7(2).
                                  MET means a unit of measurement of the level of physical exertion. 1 MET = 3.5 ml of oxygen/kg of body weight per minute, 1.0 kcal/kg of body weight per hour, or resting metabolic rate.
                                  MRCA means the Military Rehabilitation and Compensation Act 2004.
                               paraganglioma means a neoplasm of chromaffin tissue which is associated with excess secretion of catecholamines, and is located in an extra-adrenal sympathetic ganglion.
                               phaeochromocytoma means a neoplasm of chromaffin tissue which is associated with